BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Brentuximab vedotin: Phase I/II data

A retrospective analysis of 24 evaluable Hodgkin's lymphoma patients who relapsed following allogeneic stem cell transplantation from 1 of 3 open-label Phase I or II trials showed that brentuximab vedotin led to an ORR of 50%, with 9 patients in complete remission, plus 10 cases of stable disease. Median PFS was 34 weeks, while median OS has not yet been reached. Median time to objective response was 8.1 weeks. The most common >=grade...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >